
Massive Bio connects cancer patients to appropriate oncology clinical trials and accelerates enrollment for sponsors. The AI-powered platform analyzes medical records, genomic and clinical data to…

Massive Bio connects cancer patients to appropriate oncology clinical trials and accelerates enrollment for sponsors. The AI-powered platform analyzes medical records, genomic and clinical data to…
What they do: AI platform that matches cancer patients to clinical trials and provides concierge enrollment support
Founded: 2014–2015 (company sources list both years)
Headquarters: New York City
Reported patients: Tens of thousands of onboarded cancer patients (reported figures: ~60,000; another source: 160,000)
Total funding (reported): Approximately $23.8M reported across disclosed rounds
Oncology clinical-trial access and patient recruitment
2014
Hospitals and Health Care
2600000
Company reported a $2.6M financing led by Revo Capital
9000000
Company reported a $9M round to scale growth and global expansion
“Includes development finance institutions, venture investors, and philanthropic backers (examples named in disclosures: DEG, IFC, Revo Capital, Charles & Lynn Schusterman Family Philanthropies)”
| Company |
|---|
About Massive Bio Every cancer patient deserves access to treatment options. Massive Bio is an AI-powered precision medicine platform transforming how cancer patients discover and access clinical trials by eliminating the barriers of geography, financial constraints, and information asymmetry that have historically limited enrollment.
Founded in 2015 and headquartered in US, Massive Bio is scaling its impact globally by powering operations across multiple countries and bringing innovative cancer treatment options to a rapidly growing and diverse population of patients. Through our proprietary AI platform, we connect individuals to clinical trials worldwide and partner with leading pharmaceutical companies, contract research organizations (CROs), and healthcare systems to accelerate drug development and expand equitable access to cutting-edge therapies.
We're recognized as a leader in health-tech innovation. Massive Bio was featured as #4 in Fast Company's Startup 100 list for Turkey and has raised $24M total funding from impact-driven investors including Revo Capital, the International Finance Corporation, and Cavendish Impact Foundation, validating both our business model and our mission-driven approach.
The Position The Enrollment Delivery Manager owns what happens after a patient is matched: moving them through qualification, site referral, screening, consent, and enrollment. You're the person who makes sure matched patients actually get into trials.
This means working both internally and externally. Internally, you coordinate across our clinical operations, technology, operations, and customer success teams to keep handoffs tight and the funnel moving. Externally, you're the operational point of contact for clinical trial sites, sponsor clinical operations teams, CROs, and site networks, resolving issues, removing bottlenecks, and keeping enrollment on track.
You'll build and own enrollment dashboards, track conversion at every stage, and report performance to leadership and sponsors. When a trial is underperforming, you flag it early and come with a plan.
This is not a support function. You own enrollment outcomes. As the function grows, you'll build and manage a small team of Project Managers to scale delivery operations.
What We're Looking For Required:
Preferred:
Why This Role You're not joining a large team with established playbooks. You're building the delivery engine for a company where enrollment speed is the product. The role is designed to grow with a direct line to the C-level and co-founders. Within 12–18 months, you'll hire and lead your own team.
Powered by JazzHR
oEkRqEc4jo
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
80,000+
Open Roles
3,900+
New This Week